This competitive renewal proposes to continue our efforts characterizing acute myelogenous leukemia (AML) with studies that build on the significant findings that we achieved in the current funding period in both mouse models and human leukemia. In 1998 we showed that mouse AML was a multistage process involving clonal expansion of cells that resist programmed cell death. In 2000 we found that only multipotent progenitor (MPP) stage cells in human AML with AML1-ETO translocations are leukemia cells;more importantly, in the same patients, the translocation is present in normal self-renewing blood stem cells (HSC). We proposed that pre-leukemic stages of development can only occur in self-renewing clones of HSC, and that some clones progress to leukemia stem cells (LSC) at the stage of MPP. These LSC are the only cells truly responsible for driving the disease. The MPP, but not precursor HSC or progeny blast cells, transfer the leukemia to immunodeficient mice. Recent evidence has revealed cancer stem cells (CSC) to be more resistant to chemo- and radiotherapy that target their progeny proliferating cells. Thus, tumors often shrink in response to chemotherapy, but almost universally recur due to resistance of the cancer stem cells. A key implication and requirement of the cancer stem cell model is that only therapies that kill LSC/CSC can cure the patient. Thus, in order to develop CSC-targeted therapies, it is necessary to identify molecules specific to the LSC and dysregulated molecules and pathways that are critical for their pathogenesis. We propose here 3 aims designed to increase our understanding of human AML LSC in order to therapeutically target them. First, in light of new reports and our own findings, we will conduct a rigorous identification and quantification of LSC from patient samples of de novo AML, as well as investigate the normal counterparts to these LSC. Second, we will investigate the functional role of CD96 in the progression and pathogenesis of human AML, and investigate potential methods of targeting CD96 as a therapeutic strategy. During the current funding period, CD96 was identified as a candidate LSC-specific marker in two independent studies. Finally, we will examine whether CD47 expression (a 'don't eat me'signal) on leukemic cells renders them invisible to the innate (macrophage) and adaptive (dendritic cell presentation of tumor antigens) immune systems by examining the ability of various subsets of macrophages and dendritic cells to phagocytose leukemic cells and present antigen to the adaptive immune system. We will test whether a blocking anti-CD47 antibody can overcome this effect and render them susceptible to immune clearance.

Public Health Relevance

Human acute myeloid leukemia (AML) is an aggressive cancer of the bone marrow with five year overall survival rates between 30-40%. This disease is maintained by a small population of leukemia stem cells (LSC) that must be eliminated for a cure. The goal of this research is identify potential therapeutic targets for AML, by characterizing LSC markers to understand how they help AML develop and persist, including examining a mechanism of immune evasion.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA086017-14
Application #
8628747
Study Section
Molecular and Cellular Hematology (MCH)
Program Officer
Mufson, R Allan
Project Start
2000-07-01
Project End
2016-03-31
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
14
Fiscal Year
2014
Total Cost
$381,066
Indirect Cost
$150,314
Name
Stanford University
Department
Anatomy/Cell Biology
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Wernig, Gerlinde; Chen, Shih-Yu; Cui, Lu et al. (2017) Unifying mechanism for different fibrotic diseases. Proc Natl Acad Sci U S A 114:4757-4762
Gordon, Sydney R; Maute, Roy L; Dulken, Ben W et al. (2017) PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 545:495-499
Betancur, Paola A; Abraham, Brian J; Yiu, Ying Y et al. (2017) A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer. Nat Commun 8:14802
McCracken, Melissa N; George, Benson M; Kao, Kevin S et al. (2016) Normal and Neoplastic Stem Cells. Cold Spring Harb Symp Quant Biol 81:1-9
Cheah, Ming T; Chen, James Y; Sahoo, Debashis et al. (2015) CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer. Proc Natl Acad Sci U S A 112:4725-30
Weissman, Irving L (2015) Stem cells are units of natural selection for tissue formation, for germline development, and in cancer development. Proc Natl Acad Sci U S A 112:8922-8
Feng, Mingye; Chen, James Y; Weissman-Tsukamoto, Rachel et al. (2015) Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk. Proc Natl Acad Sci U S A 112:2145-50
Weissman, Irving (2015) Evolution of normal and neoplastic tissue stem cells: progress after Robert Hooke. Philos Trans R Soc Lond B Biol Sci 370:20140364
McCracken, Melissa N; Cha, Adriel C; Weissman, Irving L (2015) Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 ""Don't Eat Me"" Signals. Clin Cancer Res 21:3597-601
Beerman, Isabel; Seita, Jun; Inlay, Matthew A et al. (2014) Quiescent hematopoietic stem cells accumulate DNA damage during aging that is repaired upon entry into cell cycle. Cell Stem Cell 15:37-50

Showing the most recent 10 out of 49 publications